Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO)
Klotho Neurosciences (NASDAQ: KLTO) has announced that Dr. Robert Langer, co-founder of Moderna, has joined its Scientific Advisory Board. Dr. Langer, a renowned biotech leader and MIT professor, will contribute his expertise in neuroscience and therapeutics development. Klotho Neurosciences is developing novel therapies for neurodegenerative diseases, leveraging research on the Klotho protein, an anti-aging factor with neuroprotective potential.
The company's platform focuses on the secreted form of Klotho, s-KL, which is patented in several countries. Dr. Joseph Sinkule, Chairman and CEO of Klotho Neurosciences, expressed enthusiasm about Dr. Langer's vast experience in translational medicine and therapeutic innovation. Dr. Langer will provide guidance on the scientific and clinical development of the company's product candidates, supporting efforts to address major unmet medical needs in neurodegenerative disorders such as ALS, Alzheimer's, and Parkinson's disease.
Klotho Neurosciences (NASDAQ: KLTO) ha annunciato che Dr. Robert Langer, co-fondatore di Moderna, è entrato a far parte del suo Consiglio Consultivo Scientifico. Il Dr. Langer, un rinomato leader nel settore biotech e professore al MIT, porterà la sua esperienza nello sviluppo delle neuroscienze e delle terapie. Klotho Neurosciences sta sviluppando terapie innovative per le malattie neurodegenerative, sfruttando la ricerca sulla proteina Klotho, un fattore anti-invecchiamento con potenziale neuroprotettivo.
La piattaforma dell'azienda si concentra sulla forma secreta di Klotho, s-KL, che è brevettata in diversi paesi. Il Dr. Joseph Sinkule, Presidente e CEO di Klotho Neurosciences, ha espresso entusiasmo riguardo alla vasta esperienza del Dr. Langer nella medicina traslazionale e nell'innovazione terapeutica. Il Dr. Langer fornirà supporto per lo sviluppo scientifico e clinico dei candidati al prodotto dell'azienda, sostenendo gli sforzi per affrontare importanti esigenze mediche insoddisfatte in disturbi neurodegenerativi come SLA, Alzheimer e Parkinson.
Klotho Neurosciences (NASDAQ: KLTO) ha anunciado que Dr. Robert Langer, cofundador de Moderna, se ha unido a su Consejo Asesor Científico. El Dr. Langer, un reconocido líder en biotecnología y profesor del MIT, aportará su experiencia en neurociencia y desarrollo de terapias. Klotho Neurosciences está desarrollando terapias novedosas para enfermedades neurodegenerativas, aprovechando la investigación sobre la proteína Klotho, un factor antienvejecimiento con potencial neuroprotector.
La plataforma de la empresa se centra en la forma secretada de Klotho, s-KL, que está patentada en varios países. El Dr. Joseph Sinkule, Presidente y CEO de Klotho Neurosciences, expresó su entusiasmo por la gran experiencia del Dr. Langer en medicina traslacional e innovación terapéutica. El Dr. Langer proporcionará orientación sobre el desarrollo científico y clínico de los candidatos a productos de la empresa, apoyando los esfuerzos para abordar necesidades médicas importantes no satisfechas en trastornos neurodegenerativos como SLA, Alzheimer y Parkinson.
Klotho Neurosciences (NASDAQ: KLTO)는 Robert Langer 박사, 모더나의 공동 창립자가 과학 자문 위원회에 합류했다고 발표했습니다. Langer 박사는 저명한 생명공학 리더이자 MIT 교수로서 신경과학 및 치료제 개발 분야의 전문 지식을 기여할 것입니다. Klotho Neurosciences는 신경퇴행성 질병을 위한 혁신적인 치료법을 개발하고 있으며, 노화 방지 인자인 Klotho 단백질에 대한 연구를 활용하고 있습니다.
회사의 플랫폼은 여러 국가에서 특허를 받은 Klotho의 분비형인 s-KL에 중점을 두고 있습니다. Klotho Neurosciences의 의장 겸 CEO인 Joseph Sinkule 박사는 Langer 박사의 임상 변환 의학 및 치료 혁신에 대한 광범위한 경험에 대해 열정을 표명했습니다. Langer 박사는 회사의 제품 후보의 과학적 및 임상 개발에 대한 지침을 제공하며, ALS, 알츠하이머병 및 파킨슨병과 같은 주요한 미충족 의료 요구를 해결하기 위한 노력에 기여할 것입니다.
Klotho Neurosciences (NASDAQ: KLTO) a annoncé que Dr. Robert Langer, cofondateur de Moderna, a rejoint son Conseil Consultatif Scientifique. Le Dr. Langer, un leader reconnu dans le domaine de la biotechnologie et professeur au MIT, apportera son expertise en neurosciences et en développement thérapeutique. Klotho Neurosciences développe des thérapies novatrices pour les maladies neurodégénératives en s'appuyant sur la recherche sur la protéine Klotho, un facteur anti-âge avec un potentiel neuroprotecteur.
La plateforme de l'entreprise se concentre sur la forme sécrétée de Klotho, s-KL, qui est brevetée dans plusieurs pays. Le Dr. Joseph Sinkule, Président et CEO de Klotho Neurosciences, a exprimé son enthousiasme concernant la vaste expérience du Dr. Langer en médecine translationnelle et en innovation thérapeutique. Le Dr. Langer fournira des conseils sur le développement scientifique et clinique des candidats produits de l'entreprise, soutenant les efforts pour répondre à des besoins médicaux non satisfaits majeurs dans les troubles neurodégénératifs tels que la SLA, la maladie d'Alzheimer et la maladie de Parkinson.
Klotho Neurosciences (NASDAQ: KLTO) hat angekündigt, dass Dr. Robert Langer, Mitbegründer von Moderna, in sein Wissenschaftlicher Beirat eingetreten ist. Dr. Langer, ein renommierter Biotech-Leiter und Professor am MIT, wird sein Fachwissen in der Neurowissenschaft und in der Entwicklung von Therapeutika einbringen. Klotho Neurosciences entwickelt neuartige Therapien für neurodegenerative Erkrankungen und nutzt die Forschung über das Klotho-Protein, einen Anti-Aging-Faktor mit neuroprotektiven Eigenschaften.
Die Plattform des Unternehmens konzentriert sich auf die sekretierte Form von Klotho, s-KL, die in mehreren Ländern patentiert ist. Dr. Joseph Sinkule, Vorsitzender und CEO von Klotho Neurosciences, äußerte sich begeistert über die umfangreiche Erfahrung von Dr. Langer in der translationalen Medizin und therapeutischen Innovation. Dr. Langer wird Anleitung zur wissenschaftlichen und klinischen Entwicklung der Produktkandidaten des Unternehmens geben und die Bemühungen unterstützen, grundlegende medizinische Bedürfnisse bei neurodegenerativen Erkrankungen wie ALS, Alzheimer und Parkinson zu adressieren.
- Addition of renowned biotech leader Dr. Robert Langer to the Scientific Advisory Board
- Patents for secreted form of Klotho (s-KL) issued in USA, Europe, Hong Kong, and China
- Potential for innovative therapies in neurodegenerative diseases and healthy longevity
- None.
Renowned Biotech Leader to Contribute Expertise in Neuroscience and Therapeutics Development
NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a cutting-edge biotechnology company focused on developing innovative therapies for neurodegenerative diseases and promoting healthy longevity, is proud to announce that Dr. Robert Langer, co-founder of Moderna, has joined its Scientific Advisory Board. In addition to lending his world-class scientific expertise to guide the company’s strategic direction, this also signals Dr. Langer’s strong belief in the company’s mission and potential.
Dr. Langer is a world-renowned scientist, entrepreneur, and biotechnology pioneer. His groundbreaking work in drug delivery systems and tissue engineering has earned him numerous awards and recognition, including the prestigious National Medal of Science and the Charles Stark Draper Prize. As a co-founder of Moderna, Dr. Langer played a pivotal role in revolutionizing the biotech industry with the development of mRNA-based therapeutics, including the COVID-19 vaccine. He is a Professor at the Massachusetts Institute of Technology (MIT) and a faculty member of the Harvard–MIT Program in Health Sciences and Technology.
Klotho Neurosciences is working on the development of novel therapies aimed at addressing major unmet medical needs in neurodegenerative disorders, including ALS, Alzheimer’s and Parkinson’s disease. The company’s platform leverages groundbreaking research surrounding the Klotho protein, a powerful anti-aging factor that has shown significant neuroprotective potential in preclinical models. Patents covering the company’s secreted form of Klotho, s-KL, have been issued in the USA, Europe, Hong Kong and China.
“We are thrilled to welcome Dr. Langer to our Scientific Advisory Board,” commented Dr. Joseph Sinkule, the Chairman and CEO of Klotho Neurosciences. “His vast experience in translational medicine, biotechnology, and therapeutic innovation will be invaluable as we advance our pipeline and explore new approaches to treating devastating neurodegenerative diseases. I would also like to note that I was privileged to have worked with Bob Langer some years ago when I co-authored a scientific paper with him.”
Dr. Langer expressing his enthusiasm for joining Klotho Neurosciences commented, “I am excited to collaborate with the team at Klotho Neurosciences as they explore the therapeutic potential of the Klotho protein in combating neurodegenerative conditions. The company is working on something incredibly promising, and I’m eager to support their efforts.”
As a member of the Scientific Advisory Board, Dr. Langer will provide guidance on the scientific and clinical development of the company’s product candidates. Klotho Neurosciences is positioning itself at the forefront of the biotech sector's efforts to address one of the most pressing challenges of modern medicine, which is the treatment of neurodegenerative diseases. Dr. Langer’s involvement represents a significant milestone for the company as it moves forward in its mission to develop life-changing therapies for patients worldwide based on its patented s-KL technology platform.
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ: KLTO), a biopharmaceutical company specializing in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders. The Company obtained exclusive worldwide rights to platform technologies and knowhow to develop cutting edge protein, gene and cell therapies to treat age-related pathologies such as ALS, Alzheimer’s and Parkinson’s Disease, multiple sclerosis and rare neurodegenerative diseases. The company’s current portfolio consists of its proprietary gene therapy program using DNA and RNA as therapeutics and diagnostics. Other assets include clinical-stage programs involving antibody biologics targeting cancer and autoimmune diseases, and drug delivery via a needle-free dry powder jet autoinjector called Nanoject. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.
For more information, contact:
Eric Boyd
Investor Relations
Email: IR@klothoneuro.com
Website: www.klothoneuro.com
Forward-Looking Statements:
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
FAQ
Who joined Klotho Neurosciences' (KLTO) Scientific Advisory Board?
What is Klotho Neurosciences (KLTO) focusing on developing?
What is the significance of Dr. Robert Langer joining KLTO's Scientific Advisory Board?
What specific neurodegenerative disorders is Klotho Neurosciences (KLTO) targeting?
